Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $53.52, but opened at $48.90. Zealand Pharma A/S shares last traded at $48.90, with a volume of 179 shares trading hands.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ZLDPF. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three equities research analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.
Read Our Latest Stock Report on Zealand Pharma A/S
Zealand Pharma A/S Price Performance
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.50%. The firm had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. As a group, research analysts anticipate that Zealand Pharma A/S will post 2.95 EPS for the current fiscal year.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.
Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.
Recommended Stories
- Five stocks we like better than Zealand Pharma A/S
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
